A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT07743463 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

3003

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight
Chronic Weight Management

Interventions

DRUG: ASC30 tablets A1
DRUG: Placebo

Sponsor

Ascletis Pharma (China) Co., Limited